about
Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunitiesAssessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative studyThe epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases.Pharmacokinetics of isoniazid in low-birth-weight and premature infants.Radiology services for children in HIV- and TB-endemic regions: scope for greater collaboration between radiologists and clinicians caring for children.Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa.Tuberculosis in children.Diagnostic dilemmas in abdominal tuberculosis in children.Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.Outcome of HIV infected children with culture confirmed tuberculosis.Optimizing the detection of recent tuberculosis infection in children in a high tuberculosis-HIV burden setting.Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial.Adherence to isoniazid preventive chemotherapy: a prospective community based studyThe first 5 years of the family clinic for HIV at Tygerberg Hospital: family demographics, survival of children and early impact of antiretroviral therapy.Diversity of disease in childhood pulmonary tuberculosis.Tuberculosis Disease during Pregnancy and Treatment Outcomes in HIV-Infected and Uninfected Women at a Referral Hospital in Cape Town.Minimizing the risk of non-vertical, non-sexual HIV infection in children--beyond mother to child transmissionAntimicrobial resistance in tuberculosis: an international perspective.Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.Old and new drugs for the treatment of tuberculosis in children.Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases.Mycobacterium tuberculosis transmission is not related to household genotype in a setting of high endemicityPediatric TB: issues related to current and future treatment options.Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended dosesPharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.Tuberculosis at extremes of age.Childhood tuberculosis: an emerging and previously neglected problem.Bacteriologically confirmed tuberculosis in HIV-infected infants: disease spectrum and survival.Caring for children with drug-resistant tuberculosis: practice-based recommendations.Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.Isoniazid preventive therapy in HIV-infected and -uninfected children (0 - 14 years).Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations.Managing multidrug-resistant tuberculosis in children: review of recent developments.Fluoroquinolones for the treatment of tuberculosis in children.Antituberculosis drugs in children.
P50
Q28072376-DEE78472-4F66-4D6D-90FC-E02B3A494252Q28654702-26FEEAB6-3A14-4E20-9101-4033CBFAB5E7Q30235074-AA8B3450-68AA-4235-820A-F692B249C819Q30244341-3A7E7F73-2D71-43AA-8F85-3EFA797801E1Q30244444-10C50335-897F-40FB-9910-07523EB2820DQ33622922-3EC87963-83DF-440A-BF9E-CD5479F25619Q33754269-BDE342EA-4AD2-42FC-AD18-7197823B4FE8Q33924806-1539FBA7-DBC2-4559-9557-482FD10965EFQ34083196-1DD2050F-7A95-413B-AE00-567AE480F2A7Q34226923-E757677F-A5C0-4C5C-A8C1-921BEB2785DAQ35197257-552A5EBB-F726-4055-9785-C4A0FB51F646Q35281537-4A2B66A1-B18E-40BE-8FF7-8174CF73FACFQ35530896-783B6EBD-6578-4207-9B7F-C83F263A84E5Q35598492-28ED785F-7596-4A97-AAF1-9824E3BFB2ACQ35606554-67B50B56-8BF2-4B97-AD56-90C5C888BE6FQ35691453-013863E3-5DCF-41D4-869A-CE63B7FAD919Q36153311-31BA78B4-3218-4D39-BBC8-6C1A3DD006B2Q36157607-C69A3915-9B3A-4A51-8977-29934A84E210Q36159107-2DB58D50-0EF3-4E1C-9068-517C47A379EDQ36181914-14E92E55-C446-49F7-A447-0B4ADED67B33Q36405972-BFB6BC79-FAAE-4C4E-9404-B93FC3A60359Q36670877-FD6E06E8-48FC-41E1-B7BF-B9D6715FA514Q36730120-06CD8845-A75F-4B76-AB43-809FD6C6E6BFQ36851348-8267A36B-5C19-4B09-84E1-FB3C0F1AC95BQ37015588-2B8255AB-87DD-44B4-B97F-CF793C9FB457Q37016975-C837C500-91D8-4101-8A8E-02E4B059D1D5Q37191680-7A210E68-F3DA-4A99-A5FB-DCE3242BE350Q37573756-2BFB3457-2D51-4812-98E0-E14815ED0FC3Q37688266-390A2D24-C5D6-49E4-A81E-A1511C22E68DQ37712966-0B4D64A2-3D75-4D1B-B799-C2DC8D86A2BCQ37764939-9EBFC3EC-69C9-40D8-BA30-AC63406C000BQ37776902-5FDFB2DF-0A5F-46D4-B3BA-6FBF3758271DQ37875916-B52908D0-83A9-463B-8D5A-1CCFD1DB8894Q38043978-53DA78B4-9641-4BB4-A1EC-8E6150C464F3Q38049031-01A71DA1-73E9-4CC8-A1BF-B43E34A0CCAAQ38147380-3A57C4B5-619E-4AAD-AEF6-3E296EA26348Q38175628-D12FAFFA-0C52-4594-8F04-2EE37F3299A2Q38206068-3E7BA1EE-5AC4-4F62-B113-38842D16CED1Q38386834-4783E7A6-D700-4670-9ECB-32EDAF0FAC2BQ38533435-82EE7420-9BEC-4859-BBEA-FD1C4EEEE733
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hendrik Simon Schaaf
@ast
Hendrik Simon Schaaf
@en
Hendrik Simon Schaaf
@es
Hendrik Simon Schaaf
@nl
type
label
Hendrik Simon Schaaf
@ast
Hendrik Simon Schaaf
@en
Hendrik Simon Schaaf
@es
Hendrik Simon Schaaf
@nl
prefLabel
Hendrik Simon Schaaf
@ast
Hendrik Simon Schaaf
@en
Hendrik Simon Schaaf
@es
Hendrik Simon Schaaf
@nl
P106
P1153
7006101641
P31
P496
0000-0001-5755-4133